Just a few months after announcing their team-up, Merck KGaA and Huma Therapeutics have already checked off the first item on ...

All will be revealed during the rare disease drugmaker’s September investor day, where BioMarin will divulge the outcome from ...

AstraZeneca and Daiichi Sankyo’s trailblazing Enhertu appears to have outdone itself. | AstraZeneca and Daiichi Sankyo’s ...

Merck KGaA will shell out 300 million euros ($321 million) to build a new research center at the pharma giant’s headquarters ...

For Novo Nordisk to gain approval in the United States for its groundbreaking Awiqli (insulin icodec), it will have to first ...

With the approval of X4 Pharmaceuticals’ first product mavorixafor, there’s a new commercial rare disease player in town. | ...

While not one of the largest biopharma deals of the year so far—a crown currently worn by Gilead’s $4.43 billion acquisition ...

Regeneron and Sanofi are back with another push to show how Dupixent can help people with asthma “Du More.” The fourth ...

Pharma’s pandemic-era halo is slipping. After tracking a surge in the industry’s reputation, PatientView found patient groups ...

Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an ...

For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s ...

AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales ...